BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19815062)

  • 1. Methodology for phase selection of a weak basic drug candidate, utilizing kinetic solubility profiles in bio-relevant media.
    Furukawa S; Zhao C; Ohki Y
    Eur J Pharm Biopharm; 2010 Feb; 74(2):298-303. PubMed ID: 19815062
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethanol effects on apparent solubility of poorly soluble drugs in simulated intestinal fluid.
    Fagerberg JH; Al-Tikriti Y; Ragnarsson G; Bergström CA
    Mol Pharm; 2012 Jul; 9(7):1942-52. PubMed ID: 22651218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of solubilising effects of bile salts on an active pharmaceutical ingredient with unusual pH dependent solubility by NMR spectroscopy.
    Vogtherr M; Marx A; Mieden AC; Saal C
    Eur J Pharm Biopharm; 2015 May; 92():32-41. PubMed ID: 25720817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
    Kuentz M; Nick S; Parrott N; Röthlisberger D
    Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media.
    Fagerberg JH; Tsinman O; Sun N; Tsinman K; Avdeef A; Bergström CA
    Mol Pharm; 2010 Oct; 7(5):1419-30. PubMed ID: 20507160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New ideas about the solubility of drugs.
    Box K; Comer JE; Gravestock T; Stuart M
    Chem Biodivers; 2009 Nov; 6(11):1767-88. PubMed ID: 19937815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dissolution media simulating the proximal canine gastrointestinal tract in the fasted state.
    Arndt M; Chokshi H; Tang K; Parrott NJ; Reppas C; Dressman JB
    Eur J Pharm Biopharm; 2013 Aug; 84(3):633-41. PubMed ID: 23434923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissolution behavior of various drugs in different FaSSIF versions.
    Klumpp L; Leigh M; Dressman J
    Eur J Pharm Sci; 2020 Jan; 142():105138. PubMed ID: 31704344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is modulating solubility in simulated intestinal fluids?
    Ottaviani G; Gosling DJ; Patissier C; Rodde S; Zhou L; Faller B
    Eur J Pharm Sci; 2010 Nov; 41(3-4):452-7. PubMed ID: 20656026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced bioavailability of a poorly water-soluble weakly basic compound using a combination approach of solubilization agents and precipitation inhibitors: a case study.
    Li S; Pollock-Dove C; Dong LC; Chen J; Creasey AA; Dai WG
    Mol Pharm; 2012 May; 9(5):1100-8. PubMed ID: 22376012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of gastric pH on oral drug absorption: In vitro assessment using a dissolution/permeation system reflecting the gastric dissolution process.
    Kataoka M; Fukahori M; Ikemura A; Kubota A; Higashino H; Sakuma S; Yamashita S
    Eur J Pharm Biopharm; 2016 Apr; 101():103-11. PubMed ID: 26873006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs.
    Lehto P; Kortejärvi H; Liimatainen A; Ojala K; Kangas H; Hirvonen J; Tanninen VP; Peltonen L
    Eur J Pharm Biopharm; 2011 Aug; 78(3):531-8. PubMed ID: 21329757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in the design of fasted state simulating intestinal fluids: FaSSIF-V3.
    Fuchs A; Leigh M; Kloefer B; Dressman JB
    Eur J Pharm Biopharm; 2015 Aug; 94():229-40. PubMed ID: 26032292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biorelevant dissolution media as a predictive tool for glyburide a class II drug.
    Wei H; Löbenberg R
    Eur J Pharm Sci; 2006 Sep; 29(1):45-52. PubMed ID: 16815694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal drug solubility estimation based on simulated intestinal fluids: comparison with solubility in human intestinal fluids.
    Clarysse S; Brouwers J; Tack J; Annaert P; Augustijns P
    Eur J Pharm Sci; 2011 Jul; 43(4):260-9. PubMed ID: 21570465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API.
    McNamara DP; Childs SL; Giordano J; Iarriccio A; Cassidy J; Shet MS; Mannion R; O'Donnell E; Park A
    Pharm Res; 2006 Aug; 23(8):1888-97. PubMed ID: 16832611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced screening assays to rapidly identify solubility-enhancing formulations: high-throughput, miniaturization and automation.
    Dai WG; Pollock-Dove C; Dong LC; Li S
    Adv Drug Deliv Rev; 2008 Mar; 60(6):657-72. PubMed ID: 18222563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of drug precipitation of solubility-enhancing liquid formulations using milligram quantities of a new molecular entity (NME).
    Dai WG; Dong LC; Shi X; Nguyen J; Evans J; Xu Y; Creasey AA
    J Pharm Sci; 2007 Nov; 96(11):2957-69. PubMed ID: 17705287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lean Raman imaging for rapid assessment of homogeneity in pharmaceutical formulations.
    Brown SC; Claybourn M; Sievwright D; Fearnside V; Ashman C
    Appl Spectrosc; 2010 Apr; 64(4):442-7. PubMed ID: 20412630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salt formation to improve drug solubility.
    Serajuddin AT
    Adv Drug Deliv Rev; 2007 Jul; 59(7):603-16. PubMed ID: 17619064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.